Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Q Sun, Z Hong, C Zhang, L Wang, Z Han… - Signal transduction and …, 2023 - nature.com
Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors
IG Funingana, JS Bedia, YW Huang… - Seminars in …, 2023 - Springer
High-grade serous ovarian cancer (HGSOC) is the most lethal gynecological malignancy. Its
diagnosis at advanced stage compounded with its excessive genomic and cellular …
diagnosis at advanced stage compounded with its excessive genomic and cellular …
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition
MJM van Eijs, RJ Verheijden, SA van der Wees… - Cancer Immunology …, 2023 - Springer
Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of advanced
malignancies, but come with a diverse spectrum of immune-related adverse events (irAEs) …
malignancies, but come with a diverse spectrum of immune-related adverse events (irAEs) …
Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors
C Hou, Z Wang, X Lu - Cancer Pathogenesis and Therapy, 2024 - mednexus.org
Immune checkpoint inhibitors (ICIs) are employed in immunotherapeutic applications for
patients with weakened immune systems and can improve the ability of T cells to kill cancer …
patients with weakened immune systems and can improve the ability of T cells to kill cancer …
Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer
JFG Bejar, EY Galende, Q Zeng… - Journal for …, 2024 - pmc.ncbi.nlm.nih.gov
Background Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can
derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and …
derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and …
CD57-positive CD8+ T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer
W Sun, F Qiu, J Zheng, L Fang, J Qu, S Zhang… - NPJ Precision …, 2024 - nature.com
Immune checkpoint inhibitors have transformed the treatment landscape of non-small cell
lung cancer (NSCLC). However, accurately identifying patients who will benefit from …
lung cancer (NSCLC). However, accurately identifying patients who will benefit from …
[HTML][HTML] Clinical implications of single cell sequencing for bladder cancer
R Yadollahvandmiandoab, M Jalalizadeh… - Oncology …, 2024 - ncbi.nlm.nih.gov
Bladder cancer (BC) is the 10th most common cancer worldwide, with about 0.5 million
reported new cases and about 0.2 million deaths per year. In this scoping review, we …
reported new cases and about 0.2 million deaths per year. In this scoping review, we …
Characteristics and mechanisms of T‐cell senescence: A potential target for cancer immunotherapy
H Wu, J Li, Z Zhang, Y Zhang - European Journal of …, 2024 - Wiley Online Library
Immunosenescence, the aging of the immune system, leads to functional deficiencies,
particularly in T cells, which undergo significant changes. While numerous studies have …
particularly in T cells, which undergo significant changes. While numerous studies have …
Circulating T cells: a promising biomarker of anti-PD-(L) 1 therapy
J Hou, X Yang, S Xie, B Zhu, H Zha - Frontiers in Immunology, 2024 - frontiersin.org
Anti-PD-(L) 1 therapy has shown great efficacy in some patients with cancer. However, a
significant proportion of patients with cancer do not respond to it. Another unmet clinical …
significant proportion of patients with cancer do not respond to it. Another unmet clinical …
CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent
BLC Kinney, B Brammer, V Kansal, CJ Parrish… - …, 2024 - Taylor & Francis
ABSTRACT T lymphocytes expressing CD57 and lacking costimulatory receptors
CD27/CD28 have been reported to accumulate with aging, chronic infection, and cancer …
CD27/CD28 have been reported to accumulate with aging, chronic infection, and cancer …